首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome.
【2h】

Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome.

机译:产前倍他米松治疗后母体和脐带血清中的糖皮质激素水平可预防呼吸窘迫综合征。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Serum glucocorticoid levels were determined in 20 mothers and 43 premature infants who received prenatal betamethasone therapy for prevention of respiratory distress syndrome (RDS). Maternal betamethasone peaked at 75 microg cortisol equivalents per 100 ml 1 h after injection of 12 mg steroid and declined to half by 6 h. Betamethasone in cord blood was 14.3 microg cortisol equivalents per 100 ml at 1 h, decreased to a level of 4.7 at 20 h, and was not detected 2 days after a second dose at 24 h. After the second dose, the mean level of cortisol in cord blood was 5.9 microg per 100 ml compared with 13.05 microg per 100 ml (p less than 0.001) in untreated premature infants. The unbound glucocorticoid activity in treated infants delivered 1-10 h after the second dose (mean, 8.4 microg per 100 ml) is similar to the unbound cortisol level after birth in untreated premature infants who develop RDS. These findings indicate that (a) serum glucocorticoid levels in the physiologic stress range can induce lung maturation in the human and (b) antenatal treatment with this dose of betamethasone does not expose the human fetus to potentially harmful pharmacologic levels of steroid.
机译:在接受产前倍他米松治疗预防呼吸窘迫综合征(RDS)的20名母亲和43名早产儿中测定了血清糖皮质激素水平。母体倍他米松注射12 mg类固醇1小时后达到每100毫升75微克皮质醇当量的峰值,到6小时下降至一半。脐带血中的倍他米松在1 h时为每100 ml 14.3微克皮质醇,在20 h时降至4.7,在第二剂24 h后2天未检出。第二次给药后,脐带血中皮质醇的平均水平为每100毫升5.9微克,而未经治疗的早产儿的平均水平为每100毫升13.05微克(p小于0.001)。第二次给药后1-10小时分娩的治疗婴儿的未结合糖皮质激素活性(平均每100毫升8.4微克)类似于出生后接受RDS治疗的早产儿的未结合皮质醇水平。这些发现表明:(a)在生理压力范围内的血清糖皮质激素水平可以诱导人的肺成熟;(b)用这种剂量的倍他米松进行产前治疗不会使胎儿受到类固醇的潜在有害药理作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号